Patents by Inventor Yann Bordat

Yann Bordat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
    Publication number: 20230054612
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jan TAVERNIER, Jennyfer BULTINCK, Sarah GERLO, Gilles UZE, Franciane PAUL, Yann BORDAT
  • IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20220226441
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Application
    Filed: December 30, 2021
    Publication date: July 21, 2022
    Inventors: Jan TAVERNIER, Jose VAN DER HEYDEN, Genevieve GARCIN, Gilles UZE, Yann BORDAT
  • Fusokines involving cytokines with strongly reduced receptor binding affinities
    Patent number: 11358997
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 14, 2022
    Assignees: VIB VZW, Universiteit Gent, Centre National De La Recherche Scientifique, Université De Montpellier, Centre Hospitalier Regional Universitaire de Montpellier
    Inventors: Jan Tavernier, Jennyfer Bultinck, Sarah Gerlo, Gilles Uze, Franciane Paul, Yann Bordat
  • Immune-cell targeted bispecific chimeric proteins and uses thereof
    Patent number: 11246911
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 15, 2022
    Assignees: VIB VZW, Centre National de la Recherche Scientifique, Univeriteit Gent, Universite de Montpellier
    Inventors: Jan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
  • TARGETING OF HUMAN INTERFERON ANTAGONISTS
    Publication number: 20210238247
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: February 9, 2021
    Publication date: August 5, 2021
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • Targeting of human interferon antagonists
    Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Fusokines involving cytokines with strongly reduced receptor binding affinities
    Patent number: 10640542
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 5, 2020
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Jennyfer Bultinck, Sarah Gerlo, Gilles Uze, Franciane Paul, Yann Bordat
  • IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20190351021
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 21, 2019
    Inventors: Jan TAVERNIER, Jose VAN DER HEYDEN, Genevieve GARCIN, Gilles UZE, Yann BORDAT
  • FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
    Publication number: 20190010199
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Application
    Filed: August 14, 2018
    Publication date: January 10, 2019
    Inventors: Jan TAVERNIER, Jennyfer BULTINCK, Sarah GERLO, Gilles UZE, Franciane PAUL, Yann BORDAT
  • TARGETING OF CYTOKINE ANTAGONISTS
    Publication number: 20180334488
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: June 14, 2018
    Publication date: November 22, 2018
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • TARGETING OF CYTOKINE ANTAGONISTS
    Publication number: 20180334489
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: June 14, 2018
    Publication date: November 22, 2018
    Inventors: Jan TAVERNIER, Lennart ZABEAU, Gilles UZE, Franciane PAUL, Yann BORDAT, Genevieve GARCIN
  • Targeting of human interferon antagonists
    Patent number: 10072059
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 11, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Fusokines Involving Cytokines with Strongly Reduced Receptor Binding Affinities
    Publication number: 20180155404
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Application
    Filed: July 3, 2014
    Publication date: June 7, 2018
    Inventors: Jan TAVERNIER, Jennyfer BULTNICK, Sarah GERLO, Gilles UZÉ, Franciane PAUL, Yann BORDAT
  • TARGETING OF CYTOKINE ANTAGONISTS
    Publication number: 20180057555
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: July 6, 2017
    Publication date: March 1, 2018
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Targeting of human interferon antagonists
    Patent number: 9732135
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: August 15, 2017
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Targeting of Cytokine Antagonists
    Publication number: 20160159875
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Application
    Filed: July 1, 2014
    Publication date: June 9, 2016
    Inventors: Jan Tavemier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin